AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India

24 Sep 2024 , 06:20 PM

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSO) for the import, sale, and distribution of Durvalumab.

Shares of AstraZeneca Pharma India surged by 13% during Tuesday’s trading session, reaching an intraday high of ₹7,598. The stock has recorded a 34% gain in 2024 so far. 

Durvalumab, combined with chemotherapy, is approved as a neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) with tumors over 4 cm or node-positive, excluding EGFR mutations or ALK rearrangements.

Post-surgery, the treatment will continue with Imfinzi alone. The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals. This regulatory approval is expected to support the company’s expansion in the Indian market.